Fran

Breakthrough treatments find
a new way forward


The Alabama Drug Discovery Alliance (ADDA), a funding agency and a pharmaceutical company rolled into one, is teaming with Southern Research and UAB’s Institute for Innovation and Entrepreneurship (IIE), to help UAB investigators who are on the road to marketing their discoveries. Fran Lund, Ph.D. (pictured above), who joined UAB as Department of Microbiology chair in 2012, says, “the opportunity to even apply for an ADDA grant was a big factor in my decision to come to Birmingham.”


Microbiology Seminar Series

Dec
2

12:00pm

Dec
9

12:00pm

Dec
16

12:00pm


Join Our Mailing List!


If you would like to recieve updates for the Micro Seminar Series, please enter your email in the field below:

Invalid Input

Bedwell11

David M. Bedwell, Ph.D.
Professor
Department of Microbiology

Telephone: (205) 934-6593
Office Location: BBRB 432A, zip 2170
Email:  dbedwell@uab.edu

Research Focus:  Translation termination;
nonsense-mediated mRNA decay; genetic diseases



Biography


David Bedwell (b. 1956), Professor of Microbiology, completed his undergraduate studies in Microbiology at Purdue University (B.S. with Honors, 1979). His graduate work was done with Dr. Masayasu Nomura at the University of Wisconsin-Madison, (Ph.D., 1985) and a postdoctoral fellowship was carried out in Dr. Scott Emr's laboratory at Caltech. Dr. Bedwell joined the faculty at UAB in 1988. At the national level, he previously served as chair of the Molecular Genetics C (MGC) Study Section at the National Institutes of Health (NIH), now serves as chair of the Molecular Genetics B (MGB) Study Section. His outside interests include his family and sports.

Lab Research Focus


A major objective of research in Dr. Bedwell’s lab is to understand the mechanistic details of translation termination in eukaryotes. Besides the release factors eRF1 and eRF3, many other cellular components influence the process of translation termination. Surprisingly sophisticated cellular machineries also regulate the abundance of mRNAs based on the location of stop codons. We are using a combination of genetics, biochemistry, and cell biology in a yeast experimental system to better understand the molecular details of how these processes are carried out.

We are also investigating whether pharmacological agents can be used to suppress nonsense mutations that cause genetic diseases.  First, we are exploring whether this novel therapeutic approach can benefit patients with cystic fibrosis (CF).  CF is caused by mutations in the CFTR gene (which corresponds to the mouse Cftr gene).  We have published several papers demonstrating that drugs can suppress nonsense mutations in the CFTR gene in various CF experimental systems, including cultured CF cell lines and a CF mouse expressing a human CFTR-G542X transgene.  Most recently, we have constructed a new Cftr-G542X knock-in mouse model to explore this approach in a more physiologically relevant context.

We are also investigating whether this therapeutic approach can benefit patients with the lysosomal storage disease mucopolysaccharidosis type I-H (MPS I-H, or Hurler syndrome).  MPS I-H is caused by mutations in the human IDUA gene (which corresponds to the mouse Idua gene).  We have constructed a Idua-W392X knock-in mouse and have preliminary evidence that nonsense suppression can partially alleviate the primary biochemical defect that causes this devastating genetic disease.

Finally, the availability of these knock-in mouse models for CF and MPS I-H will allow us to explore whether the suppression of Nonsense-Mediated mRNA Decay (NMD) can further enhance the therapeutic effect provided by nonsense suppression agents.  It is hoped that either nonsense suppression alone or in combination with NMD suppression will ultimately provide a therapeutic benefit for a broad range of human genetic diseases caused by nonsense mutations.